{"id":15588,"date":"2023-08-01T01:30:00","date_gmt":"2023-07-31T17:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15588"},"modified":"2024-11-29T01:34:13","modified_gmt":"2024-11-28T17:34:13","slug":"wuxi-apptec-reports-6-28-revenue-growth-and-23-67-net-profit-increase-in-h1-2023","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15588","title":{"rendered":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023"},"content":{"rendered":"\n

China-based WuXi AppTec Co., Ltd (SHA: 603259<\/a>, HKG: 2359<\/a>) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67% YOY.<\/p>\n\n\n\n

CRDMO and CTDMO Business Model Drives Growth<\/strong>
WuXi AppTec’s unique Contract Research, Development, and Manufacturing Organization (CRDMO) and Contract Testing, Development, and Manufacturing Organization (CTDMO) business models have been instrumental in its steady growth. WuXi Chemistry generated RMB 13.47 billion (USD 1.9 billion) in revenue, up 3.8% YOY. During this period, the company managed a total of 583 molecules, including 8 commercialized and Phase III programs. Revenue from WuXi Testing reached RMB 3.09 billion, up 18.7% YOY, while WuXi Biology generated RMB 1.23 billion, up 13.0% YOY.<\/p>\n\n\n\n

Cell and Gene Therapy CTDMO Business Expansion<\/strong>
Revenue from the cell and gene therapy CTDMO business (WuXi ATU) stood at RMB 710 million (USD 99.4 million), up 16.0% YOY. In the first half of the year, WuXi AppTec helped customers complete a biologic license application (BLA) filing for a best-in-class tumor infiltrating lymphocytes (TIL) project in the US and a BLA for a lentivirus vector (LVV) project for CAR-T cell therapy in China.<\/p>\n\n\n\n

Domestic New Drug R&D Service Department Performance<\/strong>
The revenue of the domestic new drug research and development service department (WuXi DDSU) was RMB 340 million, up 24.9% YOY. During the period, the company completed 12 IND applications for clients and obtained 11 clinical trial approvals (CTAs).<\/p>\n\n\n\n

Customer Acquisition and Order Growth<\/strong>
In the first half of 2023, WuXi AppTec added more than 600 new customers. Excluding specific commercial production projects, the company’s orders in hand increased by 25% YOY. Geographically, revenue from customers in the United States leaped by 42% YOY to RMB 12.37 billion, revenue from customers in Europe increased by 19% YOY to RMB 2.22 billion, revenue from customers in China increased by 6% YOY to RMB 3.23 billion, and revenue from customers in other regions increased by 6% YOY to RMB 1.04 billion.<\/p>\n\n\n\n

Outlook for 2023<\/strong>
WuXi AppTec is expected to achieve a 5%-7% annual revenue growth in 2023, reflecting the company’s continued expansion and success in its CRDMO and CTDMO business models across various regions and therapeutic areas.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[19,27,951,1078,362],"class_list":["post-15588","post","type-post","status-publish","format-standard","hentry","category-company","tag-cro-cmo-cdmo","tag-finanical-reports","tag-hkg-2359","tag-sha-603259","tag-wuxi-apptec"],"yoast_head":"\nWuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15588\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15588\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-31T17:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T17:34:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023\",\"datePublished\":\"2023-07-31T17:30:00+00:00\",\"dateModified\":\"2024-11-28T17:34:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588\"},\"wordCount\":365,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finanical Reports\",\"HKG: 2359\",\"SHA: 603259\",\"WuXi AppTec\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15588#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15588\",\"name\":\"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-31T17:30:00+00:00\",\"dateModified\":\"2024-11-28T17:34:13+00:00\",\"description\":\"China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15588\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15588#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023 - Insight, China's Pharmaceutical Industry","description":"China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15588","og_locale":"en_US","og_type":"article","og_title":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15588","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-31T17:30:00+00:00","article_modified_time":"2024-11-28T17:34:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15588#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15588"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023","datePublished":"2023-07-31T17:30:00+00:00","dateModified":"2024-11-28T17:34:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15588"},"wordCount":365,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finanical Reports","HKG: 2359","SHA: 603259","WuXi AppTec"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15588#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15588","url":"https:\/\/flcube.com\/?p=15588","name":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-31T17:30:00+00:00","dateModified":"2024-11-28T17:34:13+00:00","description":"China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15588#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15588"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15588#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15588"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15588\/revisions"}],"predecessor-version":[{"id":15589,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15588\/revisions\/15589"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}